08-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-26 Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
01-23 Bavarian Nordic A/S Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil CI
12-10 Psivant Therapeutics, Inc. announced that it has received $47.5 million in funding from YK Bioventures, Samsara BioCapital LLC, Roivant Sciences Ltd., LSV Capital Management, LLC, Eurofarma Laboratórios S.A. and other investors CI
11-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
21/10/25 Mentis Care, Inc Appoints Hassan Kotob as Chief Executive Officer CI
21/10/25 SK Biopharmaceuticals Co., Ltd. Launches Joint Venture with Eurofarma for Ai-Based Epilepsy Management Platform CI
22/08/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
16/05/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/03/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
17/03/25 Eurofarma Laboratórios S.A. acquired 60% stake in Klibra Agenciamento de Marcas e Negócios for approximately BRL 160 million. CI
15/11/24 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
Manager TitleAgeSince
Chief Executive Officer - 23/11/2021
Investor Relations Contact 40 23/11/2021
Director TitleAgeSince
Chairman - 23/11/2021
Director/Board Member 58 23/11/2021
Director/Board Member 50 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
10/01/25 Buy 1,644,236 0.1665%
04/12/24 Sell 15,405,639 1.5600%
04/12/24 Buy 15,405,639 1.5600%

Financials

2024 2025
Net sales 10.97B 2.1B 1.86B 1.74B 1.58B 2.99B 202B 3.02B 21.04B 8.15B 103B 7.87B 7.7B 331B 12.48B 2.38B 2.12B 1.98B 1.8B 3.4B 229B 3.43B 23.92B 9.27B 117B 8.95B 8.76B 376B
Net income 117M 22.41M 19.91M 18.58M 16.94M 31.94M 2.15B 32.24M 225M 87.14M 1.1B 84.13M 82.3M 3.53B 571M 109M 97.01M 90.54M 82.52M 156M 10.5B 157M 1.1B 425M 5.37B 410M 401M 17.22B
Net Debt - -
  1. Stock Market
  2. Stocks
  3. EUFA3 Stock